Exelixis
EXEL
#1702
Rank
HK$98.65 B
Marketcap
HK$392.48
Share price
-1.90%
Change (1 day)
10.64%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): HK$24.45

According to Exelixis's latest financial reports the company's current EPS (TTM) is HK$24.51. In 2025 the company made an earnings per share (EPS) of HK$22.63.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$24.458.05%
2025HK$22.63
2023HK$5.1114.61%
2022HK$4.46-22.97%
2021HK$5.79100%
2020HK$2.90-65.09%
2019HK$8.30-53.91%
2018HK$18.01333.96%
2017HK$4.15-260.61%
2016-HK$2.58-58.75%
2015-HK$6.26-42.45%
2014-HK$10.885.3%
2013-HK$10.33

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
HK$68.40 179.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
HK$10.26-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
HK$113.37 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
HK$20.04-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
HK$27.85 13.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
HK$27.87 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
HK$30.43 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-HK$28.73-217.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-HK$6.58-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA